When prostate cancer spreads and becomes resistant to standard treatments, options can run thin. A small study from a single Italian clinic tested a targeted radiation therapy called 177Lu-PSMA-617 in 48 men with this advanced, castration-resistant disease. The treatment delivers radiation directly to cancer cells by targeting a protein called PSMA on their surface.
The results offer a glimpse of potential. Among the 44 men evaluated for response, half saw their PSA levels—a marker of cancer activity—drop by at least 50%. After one year, nearly 88% of the men were still alive, and the median overall survival was just under 19 months. The treatment was generally well-tolerated, with mostly mild side effects and rare serious toxicities.
It's crucial to view these findings in context. This was a phase II study with no comparison group, so we don't know how this treatment stacks up against other therapies. The results come from one clinic and a small group of patients, which limits how broadly we can apply them. The data support doing more research to figure out the best dose, timing, and how this treatment might fit with others, but they are not yet practice-changing.